Edition:
United States

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.43USD
14 Aug 2018
Change (% chg)

$-0.20 (-2.32%)
Prev Close
$8.63
Open
$8.60
Day's High
$8.68
Day's Low
$8.38
Volume
64,828
Avg. Vol
98,684
52-wk High
$14.62
52-wk Low
$4.89

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $828.97
Shares Outstanding(Mil.): 94.42
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -0.99 -- --
ROI: -43.84 1.42 12.88
ROE: -47.00 0.52 15.04

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

May 09 2018

BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

Mar 15 2018

BRIEF-Adaptimmune Announces Responses In Second Solid Tumor Indication

* ADAPTIMMUNE ANNOUNCES RESPONSES IN SECOND SOLID TUMOR INDICATION WITH NY-ESO SPEAR T-CELLS

Mar 15 2018

Earnings vs. Estimates